Core Viewpoint - Koyuan Pharmaceutical (301281.SZ) has announced a major asset restructuring plan involving the acquisition of 99.42% equity in Shandong Hongjitang Pharmaceutical Group Co., Ltd. through the issuance of shares and cash payments, leading to a significant stock price increase of 20.01% to 29.21 yuan per share [1] Group 1: Transaction Details - The transaction involves the acquisition of equity from 39 counterparties, including Lino Investment Holding Group Co., Ltd. and Lino Group Co., Ltd. [1] - The stock has been suspended since October 8, 2024, and will resume trading on October 22, 2024 [1] - The transaction is classified as a major asset restructuring and an associated transaction, but it does not constitute a restructuring listing [1] Group 2: Financial Aspects - The issuance price for the shares will not be lower than 80% of the average trading price over the last 20 trading days, which is set at 16.73 yuan per share [2] - The total amount of funds raised through the issuance will not exceed 100% of the transaction price for the asset purchase, with the number of shares issued not exceeding 30% of the total share capital post-transaction [2] Group 3: Use of Proceeds - The raised funds will be allocated for cash consideration for the transaction, intermediary fees, transaction taxes, working capital, and project construction of the target company [3] - The proportion of funds used for working capital and debt repayment will not exceed 25% of the transaction price or 50% of the total raised funds [3] Group 4: Company Background - Koyuan Pharmaceutical was established in 2004 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 108.29 million yuan [3] - The actual controller of the company is Gao Yuankun, who indirectly controls 34.48% of the company's shares through Lino Group and Lino Investment [3]
科源制药复牌20CM涨停 拟向控股股东等收购宏济堂股权